Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the ...

Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

The Imaging division reported a 6.6% revenue gain on the year, posting $2.55 billion. Advanced Visualization Solutions tallied gained 5.9% at $1.5 billion, and Pharmaceutical Diagnostics were up 22.3% ...

Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. | ...

Quell Therapeutics is pressing pause on an engineered regulatory T (Treg) cell therapy for liver transplant patients in order to focus resources on a preclinical autoimmune candidate. | Quell ...

Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...